ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Vizient ‘Tech Watch: Pediatrics’ Examines Increase in Telehealth, Regulatory Requirements for Sedation and Developments in COVID Vaccines

Vizient, Inc. today released “Tech Watch: Pediatrics, Vol. 7,” featuring a report on increases in telehealth services for children, a look at regulatory requirements surrounding sedation and the latest COVID vaccine information for patients under 16. The full report can be accessed here: https://info.vizientinc.com/pediatric-tech-watch-vol7-Q2-2021

“While the pediatric patient population has initially been far less affected by COVID-19 compared to adults, the pandemic has still had an impact,” said Brigitte Chorey, Vizient senior director of sourcing and program management. “Telehealth visits increased significantly last year, and as life settles into a new normal, we expect that expansion to continue.”

The report provides details on emerging technologies for the pediatric market and also offers articles focused on that patient population, including:

Virtual visits propel robust digital health strategy at children’s hospitals”: Throughout 2020, approximately 18% of all pediatric evaluation and management (E&M) visits were conducted virtually. Sg2®, a Vizient company specializing in health care intelligence and market analytics, expects the broad infrastructural investments made last year in virtual health platforms — along with consumer’s widespread exposure to telehealth — will facilitate ongoing and optimized use in this care delivery model.

Pediatric sedation for comfort during procedures and correlating regulatory requirements”: Pediatric hospitals provide services for the most vulnerable and highest acuity populations, so ensuring safe sedation practices during procedures is paramount. Using data can provide leaders information to guide decisions in support of safety and quality thus fulfilling Centers for Medicare and Medicaid Services’ requirements for Quality Assurance and Performance Improvement.

COVID-19 vaccines and children”: With three vaccines approved in the U.S. for adults and older teens, the time has come to focus on vaccinating the pediatric population. At 22% of the nation’s population, experts say it’s a must to gain herd immunity. This article provides an update on authorizations and efficacy studies.

Vizient’s "Tech Watch: Pediatrics" is published twice a year. To access the full report, click here.

###

About Vizient, Inc.

Vizient, Inc. provides solutions and services that improve the delivery of high-value care by aligning cost, quality and market performance for more than 50% of the nation’s acute care providers, which includes 95% of the nation’s academic medical centers, and more than 20% of ambulatory providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $100 billion in annual purchasing volume, to improve patient outcomes and lower costs. Vizient has earned a World’s Most Ethical Company designation from the Ethisphere Institute every year since its inception. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.

.@Vizientinc “Tech Watch: Pediatrics, Vol. 7,” features increases in #telehealth for children and COVID vaccine information for patients under 16.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.